featured
Effectiveness of Cilta-Cel vs Real-World Clinical Practice Therapies in Patients With Triple Class–Exposed Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Haematologica
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Haematologica 2022 Dec 22;[EPub Ahead of Print], MV Mateos, K Weisel, T Martin, JG Berdeja, A Jakubowiak, AK Stewart, S Jagannath, Y Lin, J Diels, F Ghilotti, P Thilakarathne, NJ Perualila, J Cabrieto, B Haefliger, N Erler-Yates, C Hague, CC Jackson, JM Schecter, V Strulev, T Nesheiwat, L Pacaud, H Einsele, P MoreauFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.